GDC0575 (hydrochloride)

GDC0575 (ARRY-575) hydrochloride is a highly-selective and orally active Chk1 (IC50=1.2 nM) inhibitor. GDC0575 (ARRY-575) hydrochloride can be used for colitis-associated cancer (CAC) and colitis research[1].

Product Specifications

CAS Number

[1196504-54-7]

Product Name Alternative

ARRY-575 (hydrochloride) ; RG7741 (hydrochloride)

UNSPSC

12352005

Target

Checkpoint Kinase (Chk)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/gdc0575-hydrochloride.html

Solubility

10 mM in DMSO

Smiles

O=C(C1CC1)NC2=CNC3=NC=C(Br)C(N4C[C@H](N)CCC4)=C32.Cl

Molecular Formula

C16H21BrClN5O

Molecular Weight

414.73

References & Citations

[1]Oo ZY, et al. Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo. Clin Cancer Res. 2018 Mar 13. |[2] Laroche-Clary A, et al. CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Ann Oncol. 2018 Apr 1;29 (4) :1023-1029.|[3] Di Tullio A, et al. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun. 2017 Nov 22;8 (1) :1679.